SABCS 2022 | Clinical and genomic landscape of breast cancers carrying CCNE1 amplification

Cyclin E1 (CCNE1) plays a critical role in cell cycle regulation and its overexpression or amplification has been associated with poor outcomes in breast cancer. Antonio Marra, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares results of an investigation into clinical and genomic features of breast cancers carrying CCNE1 amplification. Allele-specific copy number and fraction genome altered (FGA) were assessed using FACETS. Whole genome doubling (WGD) status was inferred from MSK-IMPACT sequencing data. A significant difference in the proportion of CCNE1 amp between treatment-naïve and post-treatment/metastatic samples was observed. CCNE1 amp was significantly less frequently detected in hormone receptor (HR)+/HER2- breast cancers than in HR-/HER2+ and HR-/HER2- subtypes, and was particularly rare in invasive lobular breast cancers. CCNE1 amp was significantly associated with reduced median progression-free survival (PFS) versus CCNE1 non-amplification on first line treatment with CDK4/6 inhibitor plus endocrine therapy in HR+/HER2- metastatic breast cancers. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.